ReviewTravel medicine and infectious disease
Is Omicron the end of pandemic or start of a new innings?
Review in Travel medicine and infectious disease. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 47 citations in OpenAlex.
- Universal SARS-CoV-2 RT-qPCR admission screening over 21 months in a German tertiary care hospital: detection of asymptomatic infections.BMC infectious diseases · 2026Article
- Antigenic Variation and Immune Recognition Inference From the COVID-19 Pandemic: An In Silico Comparative Analysis of Spike T Cell Epitopes From the SARS-CoV-2 Variants of Concern.Influenza and other respiratory viruses · 2026Article
- Evaluating the effectiveness of COVID-19 vaccines during a period of Omicron variant predominance among Bangladeshi population: A test-negative design measurement.Human vaccines & immunotherapeutics · 2025Article
- Stimulation of Peripheral Blood Mononuclear Cells withInternational journal of molecular sciences · 2025Article
- The Omicron Wave in Tunisia: Dynamic, Diversity, and Phylogenetic Analyses.Microorganisms · 2025Article
- Geosocial Media's Early Warning Capabilities Across US County-Level Political Clusters: Observational Study.JMIR infodemiology · 2025Observational
- How politics affect pandemic forecasting: spatio-temporal early warning capabilities of different geo-social media topics in the context of state-level political leaning.Frontiers in public health · 2025Article
- The most common skin symptoms in young adults and adults related to SARS-CoV-2 virus infection.Archives of dermatological research · 2024Review
- The Course of COVID-19 and Long COVID: Identifying Risk Factors among Patients Suffering from the Disease before and during the Omicron-Dominant Period.Pathogens (Basel, Switzerland) · 2024Article
- Enhancing Immunological Memory: Unveiling Booster Doses to Bolster Vaccine Efficacy Against Evolving SARS-CoV-2 Mutant Variants.Current microbiology · 2024Review
- Omicron vs. the rest: Assessing the competitive dynamics and coinfection scenarios of COVID-19 strains on a social network.PloS one · 2024Article
- Comparison of Computed Tomography and Clinical Features Between Patients Infected with the SARS-CoV-2 Omicron Variant and the Original Strain.Infection and drug resistance · 2024Article
- Severe Loneliness and Isolation in Nursing Students during COVID-19 Lockdown: A Phenomenological Study.Healthcare (Basel, Switzerland) · 2023Article
- The global dynamic transmissibility of COVID-19 and its influencing factors: an analysis of control measures from 176 countries.BMC public health · 2023Article
- Strategic Deployment of ICU Nurses in Response to the Omicron Variant Epidemic in Shanghai.Risk management and healthcare policy · 2023Article
- SARS-CoV-2 Omicron Variant Genomic Sequences and Their Epidemiological Correlates Regarding the End of the Pandemic: In Silico Analysis.JMIR bioinformatics and biotechnology · 2023Article
- Epidemic efficacy of Covid-19 vaccination against Omicron: An innovative approach using enhanced residual recurrent neural network.PloS one · 2023Article
- Emergence of SARS-CoV-2 Omicron variant and strategies for tackling the infection.Immunity, inflammation and disease · 2022Review
- Structural Profiles of SARS-CoV-2 Variants in India.Current microbiology · 2022Article
- Omicron variant (B.1.1.529) and its sublineages: What do we know so far amid the emergence of recombinant variants of SARS-CoV-2?Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the middle of November 2021, Omicron (B.1.1.529), a novel variant of SARS-CoV-2 was identified in South Africa. Owing to continuous increasing cases with rapid transmissibility and immune evasion, the World Health Organization (WHO) has categorized this strain as a variant of concern (VOC). In total, over 60 mutations have been identified in Omicron (BA.1) and latterly, its three sub-lineages (BA.1.1, BA.2, and BA.3) have also been found with additional mutations and pathogenicity. The highly contagious Omicron causes less severe sickness than Delta, but it is still dangerous for those who have not been vaccinated. Following the unique identification of the Omicron variant, a fresh debate has erupted regarding the natural vaccines. A number of experts believe that Omicron can work as a natural vaccine, because it is similar to live attenuated vaccines in certain ways. Additionally, it was highlighted that the high rate of antibody generation in individuals cured of Omicron provide suggestive evidence in favor of those researchers who claimed Omicron acts as natural vaccine. Some disagreements also noted, as it also has tremendous health effects and high infection rate, as similar to the prior variants. This review summarizes the contradictory scenario among the scientists about Omicron variant.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.